| December 1 |
Introgen Restructures Operations to Focus on Revenue-Generating Manufacturing Capabilities |
| December 1 |
Quintiles Acquires Targeted Molecular Diagnostics |
| December 1 |
Arpida to Restructure and Focus on Key Projects |
| December 1 |
Hemispherx Biopharma Introduces Expense Reduction Program |
| December 1 |
Johnson & Johnson Announces Definitive Agreement to Acquire Mentor Corporation |
| December 1 |
TargetRx's LaunchAdvantage Offers Critical Insight for Successful Drug Introductions |
| December 1 |
Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus |
| December 1 |
Enzon Discontinues Its Plan to Spin-off Its Biotechnology Business |
| December 2 |
InSite Vision Announces Corporate Restructuring To Focus on Growth Opportunities and Conserve Resources |
| December 2 |
WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services |
| December 2 |
Titan Pharmaceuticals Announces Reduction in Force |
| December 2 |
Sinovac Releases Statement on Healive Vaccine Suspension |
| December 2 |
Epilepsy Drug May Increase Risk of Autism in Children |
| December 2 |
PhRMA Statement on JAMA Study |
| December 2 |
Brand-Name Drugs Do Not Appear Superior to Generic Drugs for Treating Cardiovascular Disease |
| December 3 |
FDA Issues Questions and Answers on Medication Guides for Erythropoiesis-stimulating Agents (ESAs). |
| December 3 |
Innohep (tinzaparin): Clinical study Stopped Early Because of Interim Finding of Increased All-cause Mortality in Patients Who Received Drug |
| December 3 |
Cell Genesys and Takeda Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer |
| December 3 |
Drug Marketing Techniques May Be Risking Patient Safety |
| December 3 |
AstraZeneca Appoints Graham Baker Vice President and Chief Financial Officer for North America |
| December 3 |
The Prescription Project Petitions FDA to Order Pharmaceutical and Medical Device Companies to Remove Illegal Internet Ads |
| December 4 |
GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. |
| December 4 |
ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones |
| December 4 |
Merck Provides 2009 Financial Guidance; Reaffirms Guidance for 2008 and 2010 |
| December 4 |
Introgen Files Voluntary Chapter 11 Petition to Facilitate Restructuring |
| December 4 |
Forest Laboratories Responds to Unsolicited Mini-Tender Offer |
| December 4 |
Economic Measures Including a Projected Corporate Restructuring and Workforce Reduction |
| December 5 |
FDA Sends AstraZeneca Letter about Seroquel |
| December 5 |
YM BioSciences Provides EU Regulatory Update |
| December 5 |
Novel Basis Identified for Tamoxifen Failure |
| December 8 |
Bristol-Myers Squibb and AstraZeneca Announce Expansion of Worldwide Collaboration to Develop and Commercialize Dapagliflozin in Japan |
| December 8 |
SDI Reports: Physicians Satisfied with Number of Sales Rep Visits |
| December 8 |
Alnylam Strengthens Intellectual Property Estate through Acquisition of Nucleonics Patent Assets |
| December 8 |
FDA Approves GlaxoSmithKline Tetanus, Diphtheria, Whooping Cough Vaccine, Boostrix, for Adults |
| December 8 |
Emisphere Announces Reorganization Plan to Strengthen Financials and Focus On Technology Application |
| December 9 |
XTL Biopharmaceuticals Implements Restructuring Plan |
| December 9 |
Electronic Prescribing System May Encourage Physicians to Choose Lower-Cost Drugs |
| December 9 |
Kuvan Receives Marketing Approval in the European Union |
| December 9 |
Merck KGaA’s Kuvan Receives Marketing Authorization in Europe |
| December 9 |
Merck Outlines Long-Term Prospects and Progress on Strategic Plan at 2008 Annual Business Briefing |
| December 10 |
Sanofi-Aventis: Changes in Organisation |
| December 10 |
Popular Class of Diabetes Drugs Doubles Risk of Fractures in Women |
| December 10 |
IMS Health Reports Annual Global Generics Prescription Sales Growth of 3.6 Percent, to $78 Billion |
| December 10 |
America’s Pharmaceutical Research Companies Enhance Voluntary Guidelines on Direct-to-Consumer Advertising |
| December 10 |
NRC Staff Proposes $3,250 Fine for Security Violations at GlaxoSmithKline Biologicals |
| December 11 |
Hospira Issues Voluntary Recall of One Lot of 20meq Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP Due to Incorrect Bar Code Label |
| December 11 |
Hovione Buys Pfizer's Loughbeg API Facility |
| December 11 |
Panacos Provides Update on Corporate Strategy |
| December 11 |
AstraZeneca Returns Worldwide Rights to IPI-504 and IPI-493 Development Programs to Infinity Pharmaceuticals |
| December 11 |
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance |
| December 11 |
The Prescription Project Criticizes New PhRMA DTCA Guidelines |
| December 11 |
Dingell, Stupak React to PhRMA's DTC Policy Revisions |
| December 11 |
Massachusetts Proposes Sweeping New Rules Governing Sales and Marketing Tactics of Pharmaceutical and Medical Device Companies |
| December 11 |
Pain Therapeutics Receives Complete Response Letter From FDA for Remoxy |
| December 12 |
FDA Requires New Safety Measures for Oral Sodium Phosphate Products to Reduce Risk of Acute Kidney Injury |
| December 12 |
AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on Symbicort |
| December 12 |
Elan Announces Resource Realignment |
| December 12 |
GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists |
| December 12 |
Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix |
| December 12 |
Bayer Strengthens Research and Development |
| December 12 |
AstraZeneca Responds to FDA Joint Advisory Committees’ Recommendation on Symbicort |
| December 12 |
Amorfix Receives Fourth Biogen Idec Investment |
| December 12 |
Johnson & Johnson Begins Tender Offer to Acquire Mentor Corporation |
| December 12 |
Allergists Respond to FDA Committee Recommendation on Asthma Medication, Encourage Patients with Questions to Contact Physicians |
| December 12 |
Sanofi-Aventis and Bristol-Myers Squibb Prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix Patent Infringement Case |
| December 12 |
Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies |
| December 15 |
Senator Grassley’s Letter to Wyeth About Medical Ghostwriting |
| December 15 |
Senator Grassley’s letter to DesignWrite Inc. about medical ghostwriting |
| December 15 |
Adventrx Exploring Strategic Options |
| December 15 |
SDI Reports: Number of Flu Vaccines Given in Physicians’ Offices Lower This Season |
| December 15 |
Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs |
| December 15 |
Titan Pharmaceuticals Announces Further Reductions in Workforce and Voluntary Delisting from the American Stock Exchange |
| December 15 |
EntreMed Focuses on Development of ENMD-2076 |
| December 15 |
Major Shareholder Jack W. Schuler Calls for Termination of Elan CEO |
| December 16 |
Akorn, Inc. Responds to FDA Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl |
| December 16 |
FDA signs contract with Entelos to Predict Cardiovascular Adverse Events |
| December 16 |
Jazz Pharmaceuticals Announces Reduction in Force to Reflect Streamlined Operations |
| December 16 |
Biogen-Idec Reports PML Case |
| December 17 |
Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis |
| December 17 |
Healthcare Costs Prevented Nearly 40 Million Americans From Filling Their Prescriptions in 2008 |
| December 17 |
Neurobiological Technologies Announces Viprinex Does Not Pass Interim Futility Analysis |
| December 17 |
National Survey Finds That in the Last Three Months Millions of Americans Are Stretching Their Drug Prescriptions, Saving Themselves Money, by Either Taking the Medication Less Often or by Taking a Smaller Dosage Than the Physician Prescribed |
| December 17 |
Study Finds Much of Private-Sector Consumer Medication Information Not Consistently Useful |
| December 17 |
FDA Requires Warnings about Risk of Suicidal Thoughts and Behavior for Antiepileptic Medications |
| December 17 |
Lundbeck Initiates Clinical Phase III Trials With Desmoteplase in Ischemic Stroke |
| December 17 |
FTC Sues Ovation Pharmaceuticals for Illegally Acquiring Drug Used to Treat Premature Babies with Life-Threatening Heart Condition |
| December 18 |
Wyeth Pharmaceuticals Acquires Thiakis Limited |
| December 18 |
FDA Announces New Recommendations on Evaluating Cardiovascular Risk in Drugs Intended to Treat Type 2 Diabetes |
| December 18 |
ViroPharma Files FOIA Complaint Seeking Administrative Record for Vancocin |
| December 19 |
Dynavax Announces Termination of Partnership With Merck for HEPLISAV Hepatitis B Vaccine |
| December 19 |
ArQule Provides Update on Early-Stage Pipeline |
| December 19 |
Targanta Announces Corporate Restructuring |
| December 19 |
Oncothyreon Announces Development Plans and Personnel Changes and Updates Financial Guidance |
| December 22 |
King Extends Tender Offer for Alpharma |
| December 22 |
GlaxoSmithKline to Cease Providing Corporate Political Contributions |
| December 22 |
GSK to Acquire BMS Pakistan |
| December 22 |
Avigen Board and Management Comment On the Company's Strategic Plans |
| December 23 |
GlaxoSmithKline and Archemix Form Strategic Alliance to Develop Aptamers to Treat Inflammatory Diseases |
| December 23 |
Wisconsin AG Van Hollen Announces Settlement In Case Against Amgen And Immunex Alleging Deceptive Manipulation Of Average Wholesale Price For Pharmaceuticals |
| December 23 |
Emory University Announces Actions Following Investigation |
| December 23 |
Rep. Barton Probes FDA Contract |
| December 23 |
Teva Completes Acquisition of Barr |
| December 23 |
New Report Highlights Dramatic Change in U.S. Drug Spending Trends, Policy Implications |
| December 23 |
KV Pharmaceutical Voluntarily Suspends All Shipments of Its Approved Tablet-Form Drugs |
| December 23 |
Ethex Corporation Initiated Nationwide Voluntary Recall of a Single Lot of Hydromorphone HCl 2 mg Tablets Due to Potential for Oversized Tablet |
| December 23 |
Abbott and Isis Announce Hart-Scott-Rodino Clearance of Abbott's Acquisition of Ibis Biosciences, a Subsidiary of Isis |
| December 24 |
FDA Sends Abbott Letter About Humira |
| December 24 |
Cytokinetics Retains Development and Commercialization Rights to Ispinesib and SB-743921 |
| December 24 |
CPI Investigates: Heart Drug Called 'Prima ry Suspect' in 667 Deaths |
| December 24 |
Among Older Adults, Prescription And Over-The-Counter Medications Are Commonly Used Together |
| December 30 |
Florida to Receive $8.5 Million in Medicaid Settlement with Pharmaceutical Company |
| December 30 |
Biovail Announces Voluntary Recall of Certain Lots of Ultram ER 100mg Tablets |
| December 30 |
King Completes Acquisition of Alpharma |
| December 30 |
Actavis Acquires Kadian; Extends Specialty Drug Portfolio in U.S. |
| December 31 |
Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc. |
| December 31 |
U.S. Navy Requested Operations Trial on FDA Hold |
| December 31 |
Sinovac Announces that Government Investigation Rules Out Healive's Role in Child's Death |
| December 31 |
PriCara Recalls 50 mcg/hr Duragesic (fentanyl transdermal system) CII Pain Patches |
